Clinical Trial Update: Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013) [Phase 1]

View source ↗

Summary

Phase 1 trial of MK-8353 in combination with pembrolizumab in advanced malignancies, including colorectal cancer, has terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• MK-8353
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Neoplasms, Colorectal Cancer | Phase 1 | Status: TERMINATED | Results posted: 2024-11-21